FPAS
NBIX icon

Focus Partners Advisor Solutions’s Neurocrine Biosciences NBIX Stock Holding History

Focus Partners Advisor Solutions’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.45M Buy
18,618
+4,074
+28% +$541K 0.02% 309
2025
Q4 		$2.06M Buy
14,544
+1,281
+10% +$186K 0.03% 303
2025
Q3 		$1.94M Buy
13,263
+8,011
+153% +$1.09M 0.02% 345
2025
Q2 		$660K Buy
+5,252
New +$602K 0.01% 585

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Focus Partners Advisor Solutions's NBIX Position: Q1 2026 in Review

Focus Partners Advisor Solutions increased its Neurocrine Biosciences (NBIX) stake by 28% in Q1 2026, buying an estimated $541K and bringing the position to 18,618 shares worth $2.45M. The position accounts for 0.02% of the portfolio, ranked #309.

Focus Partners Advisor Solutions first reported a position in NBIX in Q2 2025 and has held it in 4 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Focus Partners Advisor Solutions held 18,618 shares of Neurocrine Biosciences worth $2.45M as of Q1 2026.
  • Focus Partners Advisor Solutions bought 4,074 Neurocrine Biosciences shares in Q1 2026, an estimated $541K.
  • Neurocrine Biosciences made up 0.02% of Focus Partners Advisor Solutions's portfolio in Q1 2026, its #309 holding.
  • Focus Partners Advisor Solutions first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 4 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q1 2026, filed 13 May 2026.